Regulatory Overview
Medsafe is the primary regulatory authority responsible for the market authorisation of medicines, medical devices, diagnostics, and related health products in New Zealand. The principal governing legislation is the Medicines Act 1981, supplemented by the Medicines Regulations 1984, the Medical Devices (Database) Regulations 2003, and the Therapeutic Products Act 2023, which is progressively being implemented to consolidate and modernise the regulatory framework. Medicines require consent to distribute, obtained through a formal application to Medsafe, which evaluates quality, safety, and efficacy. Medical devices are currently managed through a registration database system rather than a full pre-market approval regime, although the Therapeutic Products Act is set to introduce a more rigorous, risk-based licensing framework for devices and diagnostics in the coming years. Digital health products are increasingly subject to regulatory scrutiny depending on their intended purpose and risk classification.
New Zealand accepts applications based on the Common Technical Document (CTD) format, and Medsafe operates an expedited pathway for products that have received prior approval from comparable overseas regulators, including the US FDA, European Medicines Agency (EMA), Health Canada, the UK MHRA, and the Australian Therapeutic Goods Administration (TGA). A key feature of the New Zealand system is the Joint Australia-New Zealand Therapeutic Products Regulatory Scheme initiative, reflecting the long-standing trans-Tasman relationship with Australia, though full harmonisation has not yet been achieved. Applicants must appoint a New Zealand-based sponsor or local representative responsible for regulatory correspondence and post-market obligations. Recent reforms under the Therapeutic Products Act 2023 aim to streamline pathways, introduce clearer device classification rules, and better accommodate software as a medical device (SaMD) and digital health technologies.
Procurement Overview
Private sector procurement in New Zealand operates through private hospitals, specialist clinics, and retail pharmacy chains, which may source products independently of PHARMAC's schedule, although the publicly funded system dominates overall health expenditure. There is no significant donor-funded procurement channel in New Zealand, given its high-income country status, and agencies such as UNICEF, the Global Fund, USAID, or Gavi do not play a material role in domestic health product supply. New Zealand does not maintain explicit local manufacturing preference policies in public procurement; however, the government has signalled interest in improving supply chain resilience following disruptions experienced during the COVID-19 pandemic. Some preference is given to sustainable and ethical supply chains as part of broader government procurement principles. For internationally sourced products, compliance with Medsafe registration and PHARMAC listing requirements remains the principal gateway to the publicly funded market, while the private market offers an alternative but smaller commercial channel.